Form 4 for VRCA Verrica Pharmaceuticals Inc.
Accepted 2025-11-25 00:00:00 ET · period of report 2025-11-25 · accession 0001579649-25-000004 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-11-25 | 2025-11-25 | VRCA | Rosenberg Noah L. | CMO | P - Purchase | $4.24 | +2,357 | 2,357 | New | +$9,994 |
| D | 2025-11-25 | 2025-11-25 | VRCA | Rosenberg Noah L. | CMO | P - Purchase | — | +589 | 589 | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-25 | P | A | 2,357 | $4.24 | 2,357 | D | — | — | |
| 2 | Derivative | Series C Warrant (right to buy) | 2025-11-25 | P | A | 589 | — | 589 | D | $6.32 · — to 2030-11-25 | 589 Common Stock | (F2) The reported securities are included within 2,357 investment units purchased by the Reporting Person for $4.2425 per investment unit. Each investment unit consists of one share of Common Stock and a Series C warrant for one fourth of a share of common stock. The Reporting Person will not be entitled to exercise any portion of a Series C Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares beneficially owned by the Reporting Person to exceed 9.99% of the number of shares of the Issuer's common stock outstanding immediately after giving effect to the exercise. (F1) Immediately exercisable. |